EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation

Tom C Zwart iD, Suzanne Bezstarosti, Federica R Achini, Marlies E J Reinders, Marco W Schilham, Sebastiaan Heidt, Henk-Jan Guchelaar, Johan W de Fijter, Dirk Jan A R Moes

British Journal of Clinical Pharmacology · 2023-04 · 89 (4) · 1471-1485

DOI: 10.1111/bcp.15608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 09.12.2022. Verfasst von Tom C Zwart und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Kidney Transplantation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Alemtuzumab is a monoclonal antibody used as induction immunosuppressive therapy in kidney transplantation. It targets CD52 on lymphocytes, inducing profound immune cell depletion upon administration. Owing to its off‐label status in kidney transplantation, its pharmacokinetic characteristics are largely unknown in this setting, and its current fixed dosing algorithm originates from other populations. We developed a population pharmacokinetic model for alemtuzumab in kidney transplant recipients and investigated the potential of personalized alemtuzumab therapy.

Methods

In total, 362 pharmacokinetic observations drawn 0‐165 days after transplantation were available from 61 adult kidney transplant recipients who received two consecutive doses of 15 mg alemtuzumab subcutaneously. A population pharmacokinetic model was developed using nonlinear mixed‐effects modelling and applied to simulate various dosing regimens.

Results

The alemtuzumab concentration‐time data were best described by a two‐compartmental model with first‐order absorption and parallel first‐order and time‐varying concentration‐dependent elimination, with between‐subject variability on the first‐order elimination (39.6%) and central distribution volume (39.6%). Alemtuzumab pharmacokinetics varied with body size, rendering lighter individuals exposed to lympholytic alemtuzumab concentrations (>0.1 mg/L) for prolonged durations as compared to their heavier peers. This between‐subject variability could be reduced through lean bodyweight‐adjusted dosing, showing a twofold to threefold reduction in the slope of the median alemtuzumab exposure over the bodyweight range.

Conclusion

Alemtuzumab displays substantial pharmacokinetic variability in kidney transplant recipients, which may warrant a personalized treatment strategy. Lean bodyweight‐adjusted dosing poses an option for individualized dosing, but further evaluation of its potential clinical benefit is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationAdultHumansAlemtuzumabImmunosuppressive AgentsAntibodies, MonoclonalImmunosuppression Therapy

Stichwörter der Autor:innen

alemtuzumabkidney transplantationpersonalized dosingpharmacokineticspopulation pharmacokinetic modelling

Substanzen

AlemtuzumabImmunosuppressive AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Paediatrics, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Internal Medicine (Nephrology) and LUMC Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Tom C Zwart

Zitieren

APA

Zwart, T. C., Bezstarosti, S., Achini, F. R., Reinders, M. E. J., Schilham, M. W., Heidt, S., Guchelaar, H. J., de Fijter, J. W., & Moes, D. J. A. R. (2023). Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation. British Journal of Clinical Pharmacology, 89(4), 1471-1485. https://doi.org/10.1111/bcp.15608

Vancouver

Zwart TC, Bezstarosti S, Achini FR, Reinders MEJ, Schilham MW, Heidt S, et al. Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation. British Journal of Clinical Pharmacology. 2023;89(4):1471-1485. doi:10.1111/bcp.15608

BibTeX
@article{Zwart2023,
  author = {Zwart, Tom C and Bezstarosti, Suzanne and Achini, Federica R and Reinders, Marlies E J and Schilham, Marco W and Heidt, Sebastiaan and Guchelaar, Henk-Jan and de Fijter, Johan W and Moes, Dirk Jan A R},
  title = {Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  volume = {89},
  number = {4},
  pages = {1471--1485},
  doi = {10.1111/bcp.15608}
}
Kostenlos starten →